Breast Cancer: Open Trials


Register for women with lymph node macrometastases where no axillary dissection is performed.

ABCSG 36/Penelope

Phase III trial to evaluate palbociclib (PD-0332991) in patients (HR-positive, HER2 normal) with primary breast cancer, with risk of relapse following neoadjuvant chemotherapy

ABCSG 41/OlympiA

A randomised, double-blind, parallel group, placebo-controlled multicentre Phase-III-study to assess the efficacy and safety of olaparib vs. placebo as adjuvant treatment in patients with germline BRCA1/2-mutations and high risk HER2-negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy.


PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer